Metabolomics as a biomarker technology in pharmaceutical R&D

Virtual event

Metabolomics as a biomarker technology in pharmaceutical R&D

May 24th, 2022
4:00 pm CET (10:00 am EST)


Participation is free of charge, but registration is required.

By entering your contact details, you agree to our Privacy policy.


Steward Graham

Isabella Gashaw, PhD

Principal Clinical Biomarker Lead, Cardiometabolism, Boehringer Ingelheim, Germany

Anna Halama

Anna Maria Halama, PhD

Assistant Professor of Research in Physiology and Biophysics, Weill Cornell Medicine, Qatar

Marissa Jones

Stefan Ledinger, MA BSc

Director | Business development
biocrates life sciences ag

During this event you will learn

  • Why better means of patient stratification are needed
  • Why metabolomics is a promising technology for biomarker research in pharmaceutical R&D
  • How metabolomics could help identify and overcome resistance mechanisms


4:00 pm (10:00 am EST)
Introduction: Why and how does metabolomics contribute to better therapies?
Stefan Ledinger, MA BSc

4:10 pm (10:10 am EST)
Multi-omics approaches for biomarker development in the pharmaceutical industry
Isabella Gashaw, PhD

4:40 pm (10:40 am EST)
Advancing cancer treatment by targeting dysregulated metabolism – A roadmap
Anna Maria Halama, PhDPhD

5:10 pm (11:10 am EST)
Wrap up
Stefan Ledinger, MA BSc

Newsletter      Literature      Imprint      Terms & Conditions      Privacy Policy

2023 © biocrates life sciences ag